ICON (ICLR) is back in focus after recent share price moves, with the stock closing at US$167.97. For investors, the key question is how this valuation lines up against its current fundamentals.

ICON’s share price has recently gained 14.91% over the past 30 days and 44.18% over 90 days. However, the year-to-date share price return is still down 10.97%, while the 1-year total shareholder return of 15.38% contrasts with the 3- and 5-year total shareholder returns, which remain in decline.

If ICON’s recent rebound has you reassessing the sector, it could be a good moment to widen your watchlist with 40 healthcare AI stocks

After a 44.18% move over 90 days that still leaves ICON down year to date, the stock now sits in a very different spot on many watchlists. Does the current price still offer an attractive trade off between risk and potential reward, or has most of the upside already been claimed by earlier buyers, as the valuation section below explores?

Most Popular Narrative: 10% Overvalued

ICON’s most followed narrative puts fair value at $153.25, which sits below the recent $167.97 close, so it frames today’s price as ahead of that view.

ICON's strategic partnerships in the midsized pharma segment and operational improvements could drive future revenue growth and net margin enhancement. • Investments in AI tools and disciplined capital deployment through share repurchases and acquisitions aim to boost earnings and expand market presence.

Want to see the math behind that gap between price and fair value? The narrative relies on steady revenue build, rising margins and a future earnings multiple that assumes healthier profitability than recent results suggest.

Result: Fair Value of $153.25 (OVERVALUED)

However, ICON still faces elevated trial cancellations and pricing pressure from other contract research companies, both of which could undermine the earnings and margin recovery that this narrative assumes.

Another View on ICON: Cash Flows Paint a Different Picture

The analyst narrative frames ICON as about 10% overvalued at $167.97 versus a fair value of $153.25, but the Simply Wall St DCF model comes out very differently. On that view, ICON is trading roughly 32% below an estimated future cash flow value of $247.94, which suggests a very different risk and reward balance.

Both approaches are looking at the same business through different lenses. Which one do you think better reflects how ICON will actually convert its backlog and margins into long term cash generation?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out ICON for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With mixed signals around ICON's valuation and outlook, this may be a suitable moment to review the underlying data, weigh the trade offs, and assess the company's 1 or more risks against its 1 or more rewards through the 2 key rewards and 2 important warning signs.

Looking for more investment ideas beyond ICON?

If ICON has sharpened your focus on valuation and quality, do not stop here. Use the tools available to compare different opportunities and pressure test your conviction.

• Broaden your hunt for quality by reviewing 44 high quality undervalued stocks that combine lower prices with solid fundamentals and could complement or contrast your view on ICON.
• Strengthen your focus on resilience by scanning solid balance sheet and fundamentals stocks screener (48 results) where financial footing is a central part of the investment case.
• Aim for income plus staying power by assessing 8 dividend fortresses that offer higher yields alongside business stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.